Menu
Search
|

Menu

Close
X

Checkpoint Therapeutics Inc CKPT.OQ (NASDAQ Stock Exchange Capital Market)

2.36 USD
-- (--)
As of Sep 18
Previous Close 2.36
Open --
Volume --
3m Avg Volume 42,247
Today’s High --
Today’s Low --
52 Week High 5.16
52 Week Low 1.50
Shares Outstanding (mil) 36.16
Market Capitalization (mil) 94.75
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
4
FY17
2
FY16
3
EPS (USD)
FY19
-0.183
FY18
-1.276
FY17
-1.001
FY16
-1.038
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

No Data Available

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector:
Industry:
Address:

2 Gansevoort St Fl 9
NEW YORK   NY   10014-1667

Phone: +1212.5544366

Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.

SPONSORED STORIES